Medication Assisted Treatment (MAT)

Discussions Fichiers Images Videos Liens Évènements Knowledge Share Tout

Source: Knudsen, H.K., Freeman, P.R., Oyler, D.R. et al. Scaling up overdose education and naloxone distribution in Kentucky: adoption and reach achieved through a “hub with many spokes” model. Addict Sci Clin Pract 18, 72 (2023). https://doi.org/10.1186/s13722-023-00426-6 Abstract Background...

Scaling up overdose education and naloxone distribution in Kentucky adoption and reach achieved through a hub with many spokes model.pdf

Source: Austin EJ, Chen J, Briggs ES, et al. Integrating Opioid Use Disorder Treatment Into Primary Care Settings. JAMA Netw Open. 2023;6(8):e2328627. doi:10.1001/jamanetworkopen.2023.28627 Key Points Question What are multidisciplinary primary care team perspectives on barriers and facilitators to...

Integrating Opioid Use Disorder Treatment Into Primary Care Settings.pdf

Source: Jones CM, Han B, Baldwin GT, Einstein EB, Compton WM. Use of Medication for Opioid Use Disorder Among Adults With Past-Year Opioid Use Disorder in the US, 2021. JAMA Netw Open. 2023;6(8):e2327488. doi:10.1001/jamanetworkopen.2023.27488 Discussion Despite guidelines recommending MOUD...

Use of Medication for Opioid Use Disorder Among Adults With Past-Year Opioid Use Disorder in the US, 2021.pdf

Source: Marel, C., Wilson, J., Darke, S., Ross, J., Slade, T., Haber, P. S., Haasnoot, K., Visontay, R., Keaveny, M., Tremonti, C., Mills, K. L., & Teesson, M. (2023). Patterns and Predictors of Heroin Use, Remission, and Psychiatric Health Among People with Heroin Dependence: Key Findings from the...

Patterns and Predictors of Heroin Use, Remission, and Psychiatric Health Among People with Heroin Dependence - Key Findings from the 18-20-Year Follow-Up of the Australian Treatment Outcome Study (ATOS)_0.pdf

Fuente: https://www.fda.gov/news-events/press-announcements/la-fda-aprueba-una-nueva-opcion-de-tratamiento-con-buprenorfina-para-el-trastorno-por-consumo-de

Para publicación inmediata: 24 de mayo del 2023

Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) aprobó la inyección subcutánea (para uso por debajo de la piel) de Brixadi (buprenorfina) de liberación prolongada para tratar el trastorno por consumo de opioides (OUD, por sus siglas en inglés) de moderado a grave. Brixadi está disponible en dos formulaciones, una inyección...

Source: https://www.fda.gov/news-events/press-announcements/fda-approves-new-buprenorphine-treatment-option-opioid-use-disorder

For Immediate Release: May 23, 2023

Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD). Brixadi is available in two formulations, a weekly injection that can be used in patients who have started treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine...

Source: https://store.samhsa.gov/sites/default/files/pep23-02-01-002.pdf This Advisory outlines how healthcare providers (i.e., obstetrician-gynecologists [OB-GYNs], primary care physicians, and other professionals who treat pregnant people) can take an active role in supporting the health of...

Advisory Evidence-Based, Whole Person Care of Pregnant People Who Have Opioid Use Disorder_0.pdf

Source: Taylor EA, Cantor JH, Bradford AC, Simon K, Stein BD. Trends in Methadone Dispensing for Opioid Use Disorder After Medicare Payment Policy Changes. JAMA Netw Open. 2023;6(5):e2314328. doi:10.1001/jamanetworkopen.2023.14328 Key Points Question Did rates of methadone dispensing for opioid use...

Trends in Methadone Dispensing for Opioid Use Disorder After Medicare Payment Policy Changes.pdf

Source: Jakubowski, A., Singh-Tan, S., Torres-Lockhart, K. et al. Hospital-based clinicians lack knowledge and comfort in initiating medications for opioid use disorder: opportunities for training innovation. Addict Sci Clin Pract 18, 31 (2023). https://doi.org/10.1186/s13722-023-00386-x Abstract...

Hospital-based clinicians lack knowledge and comfort in initiating medications for opioid use disorder opportunities for training innovation_1.pdf

Source: Onuoha, E. N., Leff, J. A., Schackman, B. R., McCollister, K. E., Polsky, D., & Murphy, S. M. (2021). Economic evaluations of pharmacologic treatment for opioid use disorder: a systematic literature review. Value in Health, 24(7), 1068-1083. Highlights There is new evidence on buprenorphine...

Click here → to read the full text

Source: D’Onofrio G, Hawk KF, Perrone J, et al. Incidence of Precipitated Withdrawal During a Multisite Emergency Department–Initiated Buprenorphine Clinical Trial in the Era of Fentanyl. JAMA Netw Open. 2023;6(3):e236108. doi:10.1001/jamanetworkopen.2023.6108 Discussion This cohort study used data...

Incidence of Precipitated Withdrawal During a Multisite Emergency Department–Initiated Buprenorphine Clinical Trial in the Era of Fentanyl.pdf

Source: Day, N., Wass, M. & Smith, K. Virtual opioid agonist treatment: Alberta’s virtual opioid dependency program and outcomes. Addict Sci Clin Pract 17, 40 (2022). https://doi.org/10.1186/s13722-022-00323-4 Abstract Background Virtually delivered healthcare (telehealth, telemedicine) has the...

Virtual opioid agonist treatment Alberta’s virtual opioid dependency program and outcomes.pdf

Source: Andraka-Christou, B., Page, C., Schoebel, V. et al. Perceptions of buprenorphine barriers and efficacy among nurse practitioners and physician assistants. Addict Sci Clin Pract 17, 43 (2022). https://doi.org/10.1186/s13722-022-00321-6 Abstract Background Medications for opioid use disorder...

Perceptions of buprenorphine barriers and efficacy among nurse practitioners and physician assistants_0.pdf

Source: Hodgins, D. C., Budd, M., Czukar, G., Dubreucq, S., Jackson, L. A., Rush, B., ... & Cameron Wild, T. (2022). Treatment of Opioid Use Disorder in Canadian Psychosocial Addiction Programs: A National Survey of Policy, Attitudes, and Practice. The Canadian Journal of Psychiatry...

Treatment of Opioid Use Disorder in Canadian Psychosocial Addiction Programs A National Survey of Policy, Attitudes, and Practice_0.pdf

Source: Pasman, E., Kollin, R., Broman, M. et al. Cumulative barriers to retention in methadone treatment among adults from rural and small urban communities. Addict Sci Clin Pract 17, 35 (2022). https://doi.org/10.1186/s13722-022-00316-3 Abstract Background Though methadone has been shown to...

Cumulative barriers to retention in methadone treatment among adults from rural and small urban communities.pdf

Source: National Academies of Sciences, Engineering, and Medicine. 2022. Methadone Treatment for Opioid Use Disorder: Improving Access through Regulatory and Legal Change: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26635. Methadone is a Food and Drug...

Click here → to read the full text

Source: Meyers-Pantele, S.A., Mittal, M.L., Jain, S. et al. The influence of poly-drug use patterns on the association between opioid agonist treatment engagement and injecting initiation assistance. Subst Abuse Treat Prev Policy 17, 39 (2022). https://doi.org/10.1186/s13011-022-00470-6 Abstract...

The influence of poly-drug use patterns on the association between opioid agonist treatment engagement and injecting initiation assistance.pdf

Methadone Then, Methadone Now. This webinar will focus on Methadone Treatment as in a historical background beginning in the mid-1960’s through 2021 and discuss how a Methadone Treatment program in Cincinnati has dealt with the many changes in treatment. It will review the changing of treatment from...

Upcoming Events

There aren't any upcoming events

All Events

Scaling up overdose education and naloxone distribution in Kentucky: adoption and reach achieved through a “hub with many spokes” model

Integrating Opioid Use Disorder Treatment Into Primary Care Settings

Use of Medication for Opioid Use Disorder Among Adults With Past-Year Opioid Use Disorder in the US, 2021

Patterns and Predictors of Heroin Use, Remission, and Psychiatric Health Among People with Heroin Dependence: Key Findings from the 18-20-Year Follow-Up of the Australian Treatment Outcome Study (ATOS).

La FDA aprueba una nueva opción de tratamiento con buprenorfina para el trastorno por consumo de opioides

FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder

Advisory: Evidence-Based, Whole Person Care of Pregnant People Who Have Opioid Use Disorder

Trends in Methadone Dispensing for Opioid Use Disorder After Medicare Payment Policy Changes

Hospital-based clinicians lack knowledge and comfort in initiating medications for opioid use disorder: opportunities for training innovation

Economic Evaluations of Pharmacologic Treatment for Opioid Use Disorder: A Systematic Literature Review

Incidence of Precipitated Withdrawal During a Multisite Emergency Department–Initiated Buprenorphine Clinical Trial in the Era of Fentanyl

Virtual opioid agonist treatment: Alberta’s virtual opioid dependency program and outcomes

Perceptions of buprenorphine barriers and efficacy among nurse practitioners and physician assistants

Treatment of Opioid Use Disorder in Canadian Psychosocial Addiction Programs: A National Survey of Policy, Attitudes, and Practice

Cumulative barriers to retention in methadone treatment among adults from rural and small urban communities

Methadone Treatment for Opioid Use Disorder Improving Access through Regulatory and Legal Change: Proceedings of a Workshop

The influence of poly-drug use patterns on the association between opioid agonist treatment engagement and injecting initiation assistance

Methadone Then, Methadone Now, An IntNSA, PCSS Joint Hosted Webinar

Upcoming Events